Myasthenia Gravis Archives - MPR

Myasthenia Gravis

Zilucoplan Gets Orphan Drug Designation for Myasthenia Gravis Treatment

The Food and Drug Administration (FDA) has granted Orphan Drug designation to zilucoplan (Ra Pharmaceuticals) for the treatment of generalized myasthenia gravis (gMG) and other rare, tissue-based complement-mediated diseases. Zilucoplan is a synthetic, macrocyclic peptide inhibitor of complement component 5 (C5) that binds to and inhibits the cleavage of C5 into C5a and C5b preventing…